Clinical trialNCT03047993CompletedPhase 1/PHASE2Interventional

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

SponsorM.D. Anderson Cancer CenterEnrollment28Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White CellsChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeIPSS Risk Category Intermediate-2+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Courtney DiNardo
M.D. Anderson Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

M D Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →Glutaminase Inhibitor CB-839

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Nov 2017
Primary completion: 16 Mar 2023
Completion: 16 Mar 2023
Last update posted: 14 May 2024
Registered enrollment: 28
Registry id: NCT03047993

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.